Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 14/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.50 |
| ▸ | PDE4A | P27815 | 12/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885267 | 0.88 | MAPT (0.43) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3193286 | 0.86 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CMAPK14 | |
| SCHEMBL4885939 | 0.86 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CMAPK14 | |
| SCHEMBL6865598 | 0.79 | PDE4D (0.78) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL1081724 | 0.79 | PDE4A (0.55) | PDE4DPDE4BPDE4APDE4CPDE5A | |
| SCHEMBL6862920 | 0.78 | PDE4B (0.53) | PDE4DPDE4BPDE4APDE4CMAPK14 | |
| SCHEMBL3199150 | 0.74 | PDE4A (0.79) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1030472 | 0.74 | PDE4A (0.54) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1030473 | 0.74 | PDE4A (0.54) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5309884 | 0.74 | PDE4D (0.67) | PDE4DPDE4BPDE4APDE4CMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | CHIESI FARMACEUTICI S.P.A.. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015226-A1 | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | PDE4D 9/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.